Alfacalcidol
Alfacalcidol is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A11: Vitamins
— A11C: Vitamin a and d, incl. combinations of the two
— A11CC: Vitamin d and analogues
— A11CC03: Alfacalcidol
M: Musculo-skeletal system drugs
— M05: Drugs for treatment of bone diseases
— M05B: Drugs affecting bone structure and mineralization
— M05BB: Bisphosphonates, combinations affecting bone structure and mineralization
— M05BB06: Alendronic acid and alfacalcidol, sequential
HCPCS
No data
Clinical
Clinical Trials
46 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Secondary hyperparathyroidism | D006962 | EFO_1001173 | — | 1 | — | 1 | 3 | 5 | |
| Osteoporosis | D010024 | EFO_0003882 | M81.0 | — | 1 | 1 | 2 | 1 | 5 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | — | — | 1 | 1 | 2 |
| Chronic renal insufficiency | D051436 | N18 | — | — | — | 1 | 1 | 2 | |
| Postmenopausal osteoporosis | D015663 | EFO_0003854 | — | — | 1 | 1 | — | 2 | |
| Diabetic nephropathies | D003928 | EFO_0000401 | — | — | — | 1 | — | 1 | |
| Metabolic bone diseases | D001851 | HP_0000938 | — | — | — | 1 | — | 1 | |
| Asthma | D001249 | EFO_0000270 | J45 | — | — | — | 1 | — | 1 |
| Systemic lupus erythematosus | D008180 | EFO_0002690 | M32 | — | — | — | 1 | — | 1 |
| Nephrotic syndrome | D009404 | EFO_0004255 | N04 | — | — | — | 1 | — | 1 |
Show 2 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Vitamin d deficiency | D014808 | EFO_0003762 | E55 | — | — | 1 | — | 2 | 3 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 1 | 1 | — | 2 | 3 |
| Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | — | — | 1 | — | — | 1 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | — | — | 1 | — | — | 1 |
| Giant cell arteritis | D013700 | EFO_1001209 | M31.6 | — | — | 1 | — | — | 1 |
| Polymyalgia rheumatica | D011111 | EFO_0008518 | M35.3 | — | — | 1 | — | — | 1 |
| Granulomatosis with polyangiitis | D014890 | EFO_0005297 | M31.3 | — | — | 1 | — | — | 1 |
| Polymyositis | D017285 | EFO_0003063 | M33.2 | — | — | 1 | — | — | 1 |
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | — | — | 1 | — | — | 1 |
| Muscle weakness | D018908 | HP_0001324 | — | — | 1 | — | — | 1 |
Show 2 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypoparathyroidism | D007011 | E20 | — | 1 | — | — | 1 | 2 | |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | 1 | — | — | — | 1 |
| Sudden death cardiac | D016757 | EFO_0004278 | — | 1 | — | — | — | 1 | |
| Chronic kidney disease-mineral and bone disorder | D012080 | EFO_1001152 | N25.0 | — | 1 | — | — | — | 1 |
| Scoliosis | D012600 | EFO_0004273 | M41 | — | 1 | — | — | — | 1 |
| Vascular calcification | D061205 | — | 1 | — | — | — | 1 | ||
| Renal insufficiency | D051437 | HP_0000083 | N19 | — | 1 | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Replacement arthroplasty hip | D019644 | — | — | — | — | 1 | 1 | ||
| Bone density | D015519 | EFO_0003923 | M85 | — | — | — | — | 1 | 1 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 1 | 1 |
| Inflammatory bowel diseases | D015212 | EFO_0003767 | — | — | — | — | 1 | 1 | |
| Skin aging | D015595 | EFO_0005422 | — | — | — | — | 1 | 1 | |
| Hyperphosphatemia | D054559 | HP_0002905 | — | — | — | — | 1 | 1 | |
| Familial hypophosphatemia | D007015 | E83.31 | — | — | — | — | 1 | 1 | |
| Rickets | D012279 | EFO_0005583 | E55.0 | — | — | — | — | 1 | 1 |
| Covid-19 | D000086382 | U07.1 | — | — | — | — | 1 | 1 | |
| Aortic dissection | D000784 | I71.0 | — | — | — | — | 1 | 1 |
Show 1 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ALFACALCIDOL |
| INN | alfacalcidol |
| Description | Alfacalcidol is a member of the class of D3 vitamins that is calciol in which the hydrogen at the 1alpha position is replaced by a hydroxy group. It is an active metabolite of cholecalciferol, which performs important functions in regulation of the calcium balance and the bone metabolism. It has a role as a bone density conservation agent. It is a member of D3 vitamins, a seco-cholestane, a hydroxycalciol and a diol. It is functionally related to a calciol. |
| Classification | Small molecule |
| Drug class | vitamin D analogs |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)C)C[C@@H](O)C[C@@H]1O |
Identifiers
| PDB | — |
| CAS-ID | 41294-56-8 |
| RxCUI | 12062 |
| ChEMBL ID | CHEMBL1601669 |
| ChEBI ID | 31186 |
| PubChem CID | 5282181 |
| DrugBank | DB01436 |
| UNII ID | URQ2517572 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,102 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
730 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more